$ERNA
Eterna Therapeutics Inc. Stock $erna

$erna Overview Financials Valuation SEC Filings Company Website

2021 Q3 Form 10-Q Financial Statement

#000114036121028301 Filed on August 13, 2021

Income Statement

Concept	2021 Q3	2021 Q2	2020 Q2
Revenue	$0.00	$0.00	$754.0K
YoY Change	-100.0%	-100.0%	-85.58%
Cost Of Revenue			$613.0K
YoY Change			-64.36%
Gross Profit			$141.0K
YoY Change			-95.98%
Gross Profit Margin			18.7%
Selling, General & Admin	$4.258M	$4.581M	$1.595M
YoY Change	105.91%	187.21%	-53.36%
% of Gross Profit			1131.21%
Research & Development	$1.467M	$5.432M
YoY Change	58.81%
% of Gross Profit
Depreciation & Amortization	$29.26K	$38.20K	$512.0K
YoY Change	-92.13%	-92.54%	-26.86%
% of Gross Profit			363.12%
Operating Expenses	$1.467M	$10.01M	$2.019M
YoY Change	58.81%	395.89%	-42.47%
Operating Profit	-$86.28M	-$10.01M	-$2.019M
YoY Change	34754.91%	395.89%
Interest Expense	-$20.21K	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	$277.1K	-$72.00K	$14.25K
YoY Change	-2306.14%	-605.44%	-115.83%
Pretax Income	-$86.06M	-$10.09M	-$2.008M
YoY Change	5637.02%	402.24%	2131.11%
Income Tax	$0.00		$15.00K
% Of Pretax Income
Net Earnings	-$86.06M	-$10.09M	-$2.033M
YoY Change	5710.62%	395.96%	1933.45%
Net Earnings / Revenue			-269.69%
Basic Earnings Per Share	-$34.03	-$0.24	-$0.12
Diluted Earnings Per Share	-$1.703M	-$0.24	-$0.12
COMMON SHARES
Basic Shares Outstanding	51.73M	42.45M	17.58M
Diluted Shares Outstanding	2.527M	42.45M	17.58M

Balance Sheet

Concept	2021 Q3	2021 Q2	2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$24.38M	$50.16M	$2.234M
YoY Change	1325.84%	2145.51%	-18.17%
Cash & Equivalents	$24.38M	$50.17M	$5.187M
Short-Term Investments
Other Short-Term Assets	$1.353M	$1.753M	$1.669M
YoY Change	44.26%	5.04%	-25.82%
Inventory
Prepaid Expenses
Receivables			$186.0K
Other Receivables			$0.00
Total Short-Term Assets	$25.76M	$51.94M	$4.089M
YoY Change	822.25%	1170.27%	-28.39%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.213M	$582.0K	$972.0K
YoY Change	507.04%	-40.12%	-84.04%
Goodwill	$2.044M	$2.044M
YoY Change
Intangibles
YoY Change
Long-Term Investments	$1.000M	$514.9K
YoY Change
Other Assets			$214.0K
YoY Change			-68.53%
Total Long-Term Assets	$13.64M	$12.77M	$2.701M
YoY Change	503.1%	372.73%	-72.8%
TOTAL ASSETS
Total Short-Term Assets	$25.76M	$51.94M	$4.089M
Total Long-Term Assets	$13.64M	$12.77M	$2.701M
Total Assets	$39.39M	$64.71M	$6.790M
YoY Change	679.47%	853.01%	-56.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$996.3K	$3.679M	$397.0K
YoY Change	262.28%	826.78%	41.79%
Accrued Expenses	$2.128M	$1.916M	$529.0K
YoY Change	235.72%	262.22%	-63.01%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$410.0K	$719.9K	$1.644M
YoY Change	-76.53%	-56.21%	48.11%
Total Short-Term Liabilities	$4.561M	$7.684M	$3.195M
YoY Change	55.65%	140.52%	-10.5%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$1.635M
YoY Change	-100.0%	-100.0%	-27.97%
Other Long-Term Liabilities	$21.79M	$22.86K	$29.00K
YoY Change		-21.16%	-99.07%
Total Long-Term Liabilities	$21.79M	$22.86K	$1.664M
YoY Change	1237.85%	-98.63%	-69.19%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.561M	$7.684M	$3.195M
Total Long-Term Liabilities	$21.79M	$22.86K	$1.664M
Total Liabilities	$26.35M	$29.53M	$4.859M
YoY Change	478.07%	507.67%	-45.83%
SHAREHOLDERS EQUITY
Retained Earnings	-$151.2M	-$65.18M
YoY Change
Common Stock	$260.2K	$223.5K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$13.04M	$53.60M	$11.76M
YoY Change
Total Liabilities & Shareholders Equity	$39.39M	$64.71M	$6.790M
YoY Change	679.47%	853.01%	-56.59%

Cashflow Statement

Concept	2021 Q3	2021 Q2	2020 Q2
OPERATING ACTIVITIES
Net Income	-$86.06M	-$10.09M	-$2.033M
YoY Change	5710.62%	395.96%	1933.45%
Depreciation, Depletion And Amortization	$29.26K	$38.20K	$512.0K
YoY Change	-92.13%	-92.54%	-26.86%
Cash From Operating Activities	-$6.423M	-$6.805M	-$1.285M
YoY Change	673.84%	429.56%	-329.46%
INVESTING ACTIVITIES
Capital Expenditures	-$6.860K	$0.00	-$10.00K
YoY Change	-84.41%	-100.0%	-103.13%
Acquisitions
YoY Change
Other Investing Activities	-$22.85M	-$460.00
YoY Change
Cash From Investing Activities	-$22.86M	-$460.00	-$10.00K
YoY Change	51855.61%	-95.4%	-96.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.500M	48.56M	1.232M
YoY Change	2314.13%	3841.56%	-716.0%
NET CHANGE
Cash From Operating Activities	-6.423M	-6.805M	-1.285M
Cash From Investing Activities	-22.86M	-460.0	-10.00K
Cash From Financing Activities	3.500M	48.56M	1.232M
Net Change In Cash	-25.78M	41.75M	-63.00K
YoY Change	3436.74%	-66377.38%	-257.5%
FREE CASH FLOW
Cash From Operating Activities	-$6.423M	-$6.805M	-$1.285M
Capital Expenditures	-$6.860K	$0.00	-$10.00K
Free Cash Flow	-$6.416M	-$6.805M	-$1.275M
YoY Change	716.29%	433.71%	-631.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0000748592
CY2021Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.5
CY2021Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.5
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-11460
	dei	Entity Registrant Name EntityRegistrantName	Brooklyn ImmunoTherapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	31-1103425
	dei	Entity Address Address Line1 EntityAddressAddressLine1	140 58th Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 2100
CY2021Q2	us-gaap	Assets Current AssetsCurrent	51941173
CY2020Q4	us-gaap	Assets Current AssetsCurrent	1732777
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	582041
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	594106
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2767804
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2092878
CY2021Q2	us-gaap	Goodwill Goodwill	2043747
CY2020Q4	us-gaap	Goodwill Goodwill	2043747
CY2021Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	6860000
CY2020Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	6860000
CY2021Q2	us-gaap	Deposit Assets DepositAssets	514881
CY2020Q4	us-gaap	Deposit Assets DepositAssets	453252
CY2021Q2	us-gaap	Assets Assets	64709646
CY2020Q4	us-gaap	Assets Assets	13776760
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3679311
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1275223
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1916126
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1051020
CY2021Q2	us-gaap	Loans Payable Current LoansPayableCurrent	410000
CY2020Q4	us-gaap	Loans Payable Current LoansPayableCurrent	410000
CY2021Q2	btx	Paycheck Protection Program Loan Current PaycheckProtectionProgramLoanCurrent	309905
CY2020Q4	btx	Paycheck Protection Program Loan Current PaycheckProtectionProgramLoanCurrent	115972
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	383923
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	273217
CY2021Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	985233
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	0
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	7684498
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3125432
CY2021Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	19290000
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	20110000
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2529422
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1905395
CY2021Q2	btx	Paycheck Protection Program Loan Non Current PaycheckProtectionProgramLoanNonCurrent	0
CY2020Q4	btx	Paycheck Protection Program Loan Non Current PaycheckProtectionProgramLoanNonCurrent	193933
CY2021Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	22863
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	22863
CY2021Q2	us-gaap	Liabilities Liabilities	29526783
CY2020Q4	us-gaap	Liabilities Liabilities	25357623
	dei	Entity Address City Or Town EntityAddressCityOrTown	Brooklyn
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.005
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44707382
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44707382
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	0
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	0
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	100134743
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	0
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-65176198
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-37380741
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	35182863
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-11580863
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	64709646
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13776760
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4620353
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1034120
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6256910
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1657595
CY2021Q2	us-gaap	Noncash Merger Related Costs NoncashMergerRelatedCosts	0
CY2020Q2	us-gaap	Noncash Merger Related Costs NoncashMergerRelatedCosts	0
	us-gaap	Noncash Merger Related Costs NoncashMergerRelatedCosts	5765407
	us-gaap	Noncash Merger Related Costs NoncashMergerRelatedCosts	0
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-820000
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	10013130
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	2019201
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	11220
	dei	City Area Code CityAreaCode	212
	dei	Local Phone Number LocalPhoneNumber	582-1199
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	51729612
CY2021Q2	us-gaap	Cash Cash	50164673
CY2020Q4	us-gaap	Cash Cash	1630455
CY2021Q2	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	23303
CY2020Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	0
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1753197
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	102322
	dei	Security12b Title Security12bTitle	Common stock, $0.005 par value per share
	dei	Trading Symbol TradingSymbol	BTX
	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.005
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	223537
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	0
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5392777
CY2020Q2	btx	Research And Development Adjustment ResearchAndDevelopmentAdjustment	-985081
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6912410
	btx	Research And Development Adjustment ResearchAndDevelopmentAdjustment	-1376140
CY2021Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0
CY2020Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0
	us-gaap	Operating Expenses OperatingExpenses	18114727
	us-gaap	Operating Expenses OperatingExpenses	3033735
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-10013130
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2019201
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18114727
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3033735
CY2021Q2	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-50000
CY2020Q2	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-9648173
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-22187
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-14245
CY2021Q2	us-gaap	Other Expenses OtherExpenses	72187
CY2020Q2	us-gaap	Other Expenses OtherExpenses	14245
	us-gaap	Other Expenses OtherExpenses	9672924
	us-gaap	Other Expenses OtherExpenses	18923
CY2021Q2	btx	Stock Issued During Period Value Acquisitions1 StockIssuedDuringPeriodValueAcquisitions1	-157
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10202
CY2021Q2	btx	Stock Issued During Period Value In Lieu Of Dividends StockIssuedDuringPeriodValueInLieuOfDividends	0
	btx	Stock Issued During Period Value Rights Offering Membership Units StockIssuedDuringPeriodValueRightsOfferingMembershipUnits	10500000
	btx	Adjustments To Additional Paid In Capital Elimination Historical Member Equity AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity	0
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-24751
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-18923
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-10085317
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-2033446
	us-gaap	Net Income Loss NetIncomeLoss	-27787651
	us-gaap	Net Income Loss NetIncomeLoss	-3052658
CY2021Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	7806
CY2020Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	7806
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10093123
CY2020Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2033446
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-27795457
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3052658
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.79
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.79
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42448188
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42448188
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17583489
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17583489
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35187292
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35187292
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17542750
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17542750
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-4421275
CY2021Q2	btx	Stock Issued During Period Value Stock Purchase Agreement StockIssuedDuringPeriodValueStockPurchaseAgreement	48524918
CY2021Q2	btx	Stock Issued During Period Value Forfeiture Of Unvested Restricted Stock StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock	0
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1154492
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-10085317
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	35182863
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-11580863
	btx	Stock Issued During Period Value New Issues Of Preferred Stock Retained By Stockholders StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders	0
	btx	Stock Issued During Period Value Stock Purchase Agreement StockIssuedDuringPeriodValueStockPurchaseAgreement	48524918
	btx	Stock Issued During Period Value Forfeiture Of Unvested Restricted Stock StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock	0
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1573393
	us-gaap	Net Income Loss NetIncomeLoss	-27787651
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	35182863
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	9059125
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	22734
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-2033446
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	11760226
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	9743103
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	45468
	us-gaap	Stockholders Equity Other StockholdersEquityOther	5024313
	us-gaap	Net Income Loss NetIncomeLoss	-3052658
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	11760226
	btx	Stock Issued During Period Value Acquisitions1 StockIssuedDuringPeriodValueAcquisitions1	8177457
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	47638
	us-gaap	Share Based Compensation ShareBasedCompensation	1573393
	us-gaap	Share Based Compensation ShareBasedCompensation	45468
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	148702
	us-gaap	Partners Capital Account Acquisitions PartnersCapitalAccountAcquisitions	0
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	5765407
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10202
	btx	Stock Issued During Period Value In Lieu Of Dividends StockIssuedDuringPeriodValueInLieuOfDividends	0
CY2020Q2	us-gaap	Stockholders Equity Other StockholdersEquityOther	4711813
	us-gaap	Net Income Loss NetIncomeLoss	-27787651
	us-gaap	Net Income Loss NetIncomeLoss	-3052658
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	63485
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	0
	us-gaap	Noncash Merger Related Costs NoncashMergerRelatedCosts	5765407
	us-gaap	Noncash Merger Related Costs NoncashMergerRelatedCosts	0
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-9648173
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-820000
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4680
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1509284
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	79175
	btx	Increase Decrease In Deposit Assets And Other Non Current Assets IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets	26909
	btx	Increase Decrease In Deposit Assets And Other Non Current Assets IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets	84915
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2844135
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-942836
	btx	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-138895
	btx	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-468
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	10324
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10234764
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4056622
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	26177
	us-gaap	Proceeds From Sales Of Assets Investing Activities ProceedsFromSalesOfAssetsInvestingActivities	147262
	us-gaap	Proceeds From Sales Of Assets Investing Activities ProceedsFromSalesOfAssetsInvestingActivities	0
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	118594
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	265856
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-26177
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	48524918
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	10202
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	309905
	btx	Payments Of Paycheck Protection Program Loan PaymentsOfPaycheckProtectionProgramLoan	531994
	btx	Payments Of Paycheck Protection Program Loan PaymentsOfPaycheckProtectionProgramLoan	0
	us-gaap	Interest Paid Net InterestPaidNet	0
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1630455
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5100819
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50164673
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5186675
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	10500000
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	3858750
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	58503126
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4168655
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	48534218
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	85856
	us-gaap	Interest Paid Net InterestPaidNet	0
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0
	btx	Issuance Of Common Stock For Series A Preferred Stock Dividend IssuanceOfCommonStockForSeriesAPreferredStockDividend	7806
	btx	Issuance Of Common Stock For Series A Preferred Stock Dividend IssuanceOfCommonStockForSeriesAPreferredStockDividend	0
	us-gaap	Stock Issued1 StockIssued1	8177457
	us-gaap	Stock Issued1 StockIssued1	0
	btx	Forfeiture Of Unvested Restricted Stock ForfeitureOfUnvestedRestrictedStock	-60
	btx	Forfeiture Of Unvested Restricted Stock ForfeitureOfUnvestedRestrictedStock	0
	btx	Noncash Or Part Noncash Acquisition Preferred Shares Issued In Connection With Reverse Merger NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger	781
	btx	Noncash Or Part Noncash Acquisition Preferred Shares Issued In Connection With Reverse Merger NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger	0
	btx	Initial Measurement Of Right Of Use Assets And Liabilities InitialMeasurementOfRightOfUseAssetsAndLiabilities	873629
	btx	Initial Measurement Of Right Of Use Assets And Liabilities InitialMeasurementOfRightOfUseAssetsAndLiabilities	0
CY2021Q2	us-gaap	Cash Cash	50164673
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-65176198
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-820000
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-9648173
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-10085317
	us-gaap	Net Income Loss NetIncomeLoss	-27787651
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10234764
	us-gaap	Lease Cost LeaseCost	282879
CY2021Q2	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-27795457
CY2020Q2	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-3060464
CY2021Q2	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	-0.79
CY2021Q2	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.79
CY2020Q2	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.17
CY2020Q2	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	-0.17
	btx	Percentage Of Royalty Revenue Assumed Until2029 PercentageOfRoyaltyRevenueAssumedUntil2029	0.13
	btx	Percentage Of Royalty Revenue Assumed From2030 To2038 PercentageOfRoyaltyRevenueAssumedFrom2030To2038	0.07
	btx	Percentage Of Royalty Revenue Post Patent Decline Year One PercentageOfRoyaltyRevenuePostPatentDeclineYearOne	0.50
	btx	Percentage Of Royalty Revenue Post Patent Decline After Year One PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne	0.10
	btx	Percentage Of Income Taxes Projected In Terms Of Royalty Savings PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings	0.26
	btx	Percentage Of Weighted Average Cost Of Capital PercentageOfWeightedAverageCostOfCapital	0.26
CY2021Q2	btx	Operating Lease Area OperatingLeaseArea	2700
	btx	Annual Rent Per Square Foot AnnualRentPerSquareFoot	56.00
	us-gaap	Operating Lease Payments OperatingLeasePayments	25331
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	163752
	us-gaap	Operating Lease Cost OperatingLeaseCost	314617
CY2021Q2	us-gaap	Sublease Income SubleaseIncome	21045
	us-gaap	Sublease Income SubleaseIncome	42090
CY2021Q2	us-gaap	Variable Lease Cost VariableLeaseCost	1350
	us-gaap	Variable Lease Cost VariableLeaseCost	10352
CY2021Q2	us-gaap	Lease Cost LeaseCost	144057
CY2021Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	6860000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2092878
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	148702
	btx	Addition Of Operating Lease Rightof Use Asset AdditionOfOperatingLeaseRightofUseAsset	823628
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2767804
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2178612
	btx	Principal Payments On Operating Lease Liabilities PrincipalPaymentsOnOperatingLeaseLiabilities	-138895
	btx	Addition Of Operating Lease Liability AdditionOfOperatingLeaseLiability	873628
CY2021Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	2913345
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2529422
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	383923
CY2021Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y4M24D
CY2021Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1276
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	361318
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	751861
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	769864
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	787275
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	805192
CY2021Q2	btx	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	514174
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3989684
CY2021Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1076339
CY2021Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	2913345
CY2019Q2	btx	Area Of Sublease Space Currently Rented AreaOfSubleaseSpaceCurrentlyRented	999
	btx	Lessee Sublease Term Of Contract LesseeSubleaseTermOfContract	P8Y
CY2019Q2	btx	Percentage Of Lessee Sublease Increase In Annual Lease Rent Payments PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments	0.0225
CY2021Q2	btx	Sale Leaseback Transactions Future Minimum Sublease Rentals Remainder Of Fiscal Year SaleLeasebackTransactionsFutureMinimumSubleaseRentalsRemainderOfFiscalYear	40628
CY2021Q2	btx	Sale Leaseback Transactions Future Minimum Sublease Rentals Next Twelve Months SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths	82419
CY2021Q2	btx	Sale Leaseback Transactions Future Minimum Sublease Rentals Within Two Years SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears	84194
CY2021Q2	btx	Sale Leaseback Transactions Future Minimum Sublease Rentals Within Three Years SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears	86010
CY2021Q2	btx	Sale Leaseback Transactions Future Minimum Sublease Rentals Within Four Years SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears	87867
CY2021Q2	btx	Sale Leaseback Transactions Future Minimum Sublease Rentals Four Years Thereafter SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFourYearsThereafter	74590
CY2021Q2	btx	Sale Leaseback Transactions Future Minimum Sublease Rentals SaleLeasebackTransactionsFutureMinimumSubleaseRentals	455708
CY2020Q4	btx	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	207468
	us-gaap	Sublease Income SubleaseIncome	40054
CY2021Q2	us-gaap	Goodwill Goodwill	2043747
CY2021Q2	btx	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	719023
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1154492
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22734
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1573393
	btx	Share Based Payment Arrangement Modification Expense ShareBasedPaymentArrangementModificationExpense	249905
CY2020Q4	btx	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	399893
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	45468
CY2021Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	385935
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	293534
CY2021Q2	btx	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	631563
CY2021Q2	us-gaap	Interest Payable Current InterestPayableCurrent	179605
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	150125
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1916126
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1051020
CY2021Q2	btx	Number Of Stock Option Grant Made NumberOfStockOptionGrantMade	2
CY2021Q1	us-gaap	Stock Issued During Period Shares Reverse Stock Splits StockIssuedDuringPeriodSharesReverseStockSplits	1514373
CY2021Q1	btx	Stock Issued During Period Shares Acquisitions1 StockIssuedDuringPeriodSharesAcquisitions1	1067879

Files In Submission

Name	View Source	Status
0001140361-21-028301-index-headers.html	Edgar Link	pending
0001140361-21-028301-index.html	Edgar Link	pending
0001140361-21-028301.txt	Edgar Link	pending
0001140361-21-028301-xbrl.zip	Edgar Link	pending
brhc10027925_10q.htm	Edgar Link	pending
brhc10027925_10q_htm.xml	Edgar Link	completed
brhc10027925_ex31-1.htm	Edgar Link	pending
brhc10027925_ex31-2.htm	Edgar Link	pending
brhc10027925_ex32-1.htm	Edgar Link	pending
brhc10027925_ex32-2.htm	Edgar Link	pending
btx-20210630.xsd	Edgar Link	pending
btx-20210630_cal.xml	Edgar Link	unprocessable
btx-20210630_def.xml	Edgar Link	unprocessable
btx-20210630_lab.xml	Edgar Link	unprocessable
btx-20210630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image00001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ERNA
Eterna Therapeutics Inc. Stock $erna

2021 Q3 Form 10-Q Financial Statement

#000114036121028301 Filed on August 13, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ERNA Eterna Therapeutics Inc. Stock $erna

2021 Q3 Form 10-Q Financial Statement

#000114036121028301 Filed on August 13, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ERNA
Eterna Therapeutics Inc. Stock $erna